A protective role for endothelial nitric oxide synthase in glomerulonephritis. 2002

Peter Heeringa, and Eric Steenbergen, and Harry van Goor
Department of Clinical and Experimental Immunology, Cardiovascular Research Institute, University Maastricht, Universiteitssingel 50 6221 ER Maastricht, The Netherlands. p.heeringa@immuno.unimaas.nl

In acute glomerulonephritis (GN), increased nitric oxide (NO) production occurs, suggesting a pathophysiological role for NO in the disease process. Although NO potentially could have both toxic as well as protective effects, its exact role in the pathophysiology of GN is unclear and may depend on the NOS isoform generating NO. The protective effects of NO such as prevention of leukocyte and platelet activation and adhesion have been attributed to NO generated by endothelial nitric oxide synthase (eNOS). Evidence for a beneficial role for eNOS includes the demonstration of reduced eNOS expression in experimental models of GN as well as human biopsy specimens that is mostly likely due to endothelial cell necrosis. Reduced NO production in GN also may occur through reaction of NO with superoxide anions or the myeloperoxidase (MPO)/hypochlorous acid (HOCL) system. Further evidence has been provided by the observation that in several experimental models of GN, glomerular injury is exacerbated following treatment with non-selective NO inhibitors. Finally, the development of GN is severely aggravated in mice lacking a functional gene for eNOS as compared to wild-type mice, providing direct support for a protective role of eNOS-derived NO in acute GN.

UI MeSH Term Description Entries
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D052250 Nitric Oxide Synthase Type III A CALCIUM-dependent, constitutively-expressed form of nitric oxide synthase found primarily in ENDOTHELIAL CELLS. ECNOS Enzyme,ENOS Enzyme,Endothelial Constitutive Nitric Oxide Synthase,Endothelial Nitric Oxide Synthase,Nitric Oxide Synthase, Type III
D019001 Nitric Oxide Synthase An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE. NO Synthase,Nitric-Oxide Synthase,Nitric-Oxide Synthetase,Nitric Oxide Synthetase,Oxide Synthase, Nitric,Synthase, Nitric Oxide
D019610 Cytoprotection The process by which chemical compounds provide protection to cells against harmful agents. Cell Protection,Protection, Cell

Related Publications

Peter Heeringa, and Eric Steenbergen, and Harry van Goor
January 2003, The Journal of pathology,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
October 2002, The Journal of urology,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
June 1998, Kidney international,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
January 2014, Vitamins and hormones,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
May 1999, Arteriosclerosis, thrombosis, and vascular biology,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
January 2011, Contributions to nephrology,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
January 2015, Mediators of inflammation,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
June 2005, Proceedings of the National Academy of Sciences of the United States of America,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
August 2000, British journal of pharmacology,
Peter Heeringa, and Eric Steenbergen, and Harry van Goor
November 2021, Life sciences,
Copied contents to your clipboard!